ERα36-High Cancer-Associated Fibroblasts as an Unfavorable Factor in Triple-Negative Breast Cancer.

breast cancer cancer-associated fibroblasts estrogen receptor alpha 36 triple-negative breast cancer

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
15 Apr 2022
Historique:
received: 21 03 2022
accepted: 12 04 2022
entrez: 23 4 2022
pubmed: 24 4 2022
medline: 24 4 2022
Statut: epublish

Résumé

Background: Cancer-associated fibroblasts (CAFs) are the most abundant cell type in the tumor microenvironment (TME). Estrogen receptor alpha 36 (ERα36), the alternatively spliced variant of ERα, is described as an unfavorable factor when expressed in cancer cells. ERα can be expressed also in CAFs; however, the role of ERα36 in CAFs is unknown. Methods: Four CAF cultures were isolated from chemotherapy-naïve BC patients and characterized for ERα36 expression and the NanoString gene expression panel using isolated RNA. Conditioned media from CAF cultures were used to assess the influence of CAFs on triple-negative breast cancer (TNBC) cells using a matrigel 3D culture assay. Results: We found that ERα36high CAFs significantly induced the branching of TNBC cells in vitro (p < 0.001). They also produced a set of pro-tumorigenic cytokines compared to ERα36low CAFs, among which hepatocyte growth factor (HGF) was the main inducer of TNBC cell invasive phenotype in vitro (p < 0.001). Tumor stroma rich in ERα36high CAFs was correlated with high Ki67 expression (p = 0.041) and tumor-associated macrophages markers (CD68 and CD163, p = 0.041 for both). HGF was found to be an unfavorable prognostic factor in TCGA database analysis (p = 0.03 for DFS and p = 0.04 for OS). Conclusions: Breast cancer-associated fibroblasts represent distinct subtypes based on ERα36 expression. We propose that ERα36high CAFs could account for an unfavorable prognosis for TNBC patients.

Identifiants

pubmed: 35454913
pii: cancers14082005
doi: 10.3390/cancers14082005
pmc: PMC9024776
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : National Science Center
ID : 2016/22/E/NZ4/00664
Organisme : Ministry of Science and Higher Education
ID : IP 2014 028473

Références

Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Lancet Oncol. 2007 Mar;8(3):235-44
pubmed: 17329194
Oncotarget. 2017 Jan 31;8(5):8633-8647
pubmed: 28052009
Tumour Biol. 2016 Apr;37(4):4409-20
pubmed: 26499945
Br J Cancer. 2008 Nov 18;99(10):1623-34
pubmed: 18941460
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
Cancer Lett. 2015 Jun 1;361(2):155-63
pubmed: 25700776
Cell. 2012 Jul 6;150(1):165-78
pubmed: 22770218
Eur J Cell Biol. 2015 Dec;94(12):611-25
pubmed: 26522827
Breast Cancer Res. 2013;15(5):R82
pubmed: 24025166
Virchows Arch. 2020 Dec;477(6):767-775
pubmed: 32607685
Mol Cancer. 2016 Jan 20;15:7
pubmed: 26790618
Cell Signal. 2009 Apr;21(4):470-6
pubmed: 19110052
Expert Opin Ther Targets. 2005 Dec;9(6):1217-33
pubmed: 16300472
Biosci Rep. 2017 Apr 10;37(2):
pubmed: 28258248
Oncotarget. 2016 Jun 14;7(24):37145-37159
pubmed: 27175600
J Exp Med. 2017 Mar 6;214(3):579-596
pubmed: 28232471
Breast Cancer Res Treat. 2017 Jan;161(2):279-287
pubmed: 27888421
Breast Cancer Res Treat. 2017 Dec;166(3):709-723
pubmed: 28831645
Cancer Cell. 2004 Jul;6(1):17-32
pubmed: 15261139
Cancers (Basel). 2015 Dec 11;7(4):2443-58
pubmed: 26690480
Transl Oncol. 2019 Feb;12(2):245-255
pubmed: 30439625
PLoS One. 2009 Nov 23;4(11):e7965
pubmed: 19956757
Nat Med. 2008 May;14(5):518-27
pubmed: 18438415
Breast Cancer. 2012 Apr;19(2):170-6
pubmed: 20978953
Int J Mol Sci. 2019 Apr 16;20(8):
pubmed: 30995757
Cancer Treat Rev. 2010 Nov;36 Suppl 3:S80-6
pubmed: 21129616
Int J Cancer. 2017 Nov 1;141(9):1901-1911
pubmed: 28677228
J Steroid Biochem Mol Biol. 2011 Nov;127(3-5):231-7
pubmed: 21888973
Breast Cancer Res Treat. 2011 Feb;125(3):687-96
pubmed: 20361254
Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3:193-206
pubmed: 25917453
Ann Oncol. 2011 Aug;22(8):1736-47
pubmed: 21709140
Arch Gynecol Obstet. 2018 Jan;297(1):161-183
pubmed: 29063236
Cancers (Basel). 2019 Dec 06;11(12):
pubmed: 31817685
Drugs. 2020 Jul;80(11):1125-1131
pubmed: 32557339
Oncol Lett. 2018 Apr;15(4):5694-5702
pubmed: 29563996
Annu Rev Immunol. 2011;29:235-71
pubmed: 21219185
Int J Mol Sci. 2018 Nov 14;19(11):
pubmed: 30441809
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Nat Commun. 2019 Sep 27;10(1):4404
pubmed: 31562303
Cell Biochem Biophys. 2015 Dec;73(3):793-8
pubmed: 27259327
Carcinogenesis. 2014 Jun;35(6):1301-9
pubmed: 24374826
Steroids. 2014 Mar;81:74-80
pubmed: 24252378
Cancer Res. 2013 Jun 1;73(11):3470-80
pubmed: 23633491
Oncogenesis. 2018 Oct 5;7(10):78
pubmed: 30287850
Breast Cancer Res. 2015 Apr 08;17:52
pubmed: 25887320
Dis Model Mech. 2018 Apr 19;11(4):
pubmed: 29686035
Oncotarget. 2016 Dec 13;7(50):82889-82901
pubmed: 27756881
BMC Cancer. 2014 Oct 24;14:781
pubmed: 25344051
Clin Cancer Res. 2017 Apr 1;23(7):1710-1721
pubmed: 27702820

Auteurs

Anna Nagel (A)

Laboratory of Translational Oncology, Intercollegiate Faculty of Biotechnology, Medical University of Gdansk, 80-211 Gdansk, Poland.

Marta Popeda (M)

Laboratory of Translational Oncology, Intercollegiate Faculty of Biotechnology, Medical University of Gdansk, 80-211 Gdansk, Poland.

Anna Muchlinska (A)

Laboratory of Translational Oncology, Intercollegiate Faculty of Biotechnology, Medical University of Gdansk, 80-211 Gdansk, Poland.

Rafal Sadej (R)

Laboratory of Molecular Enzymology and Oncology, Intercollegiate Faculty of Biotechnology, Medical University of Gdansk, 80-211 Gdansk, Poland.

Jolanta Szade (J)

Department of Pathomorphology, Medical University of Gdansk, 80-211 Gdansk, Poland.

Jacek Zielinski (J)

Department of Surgical Oncology, Medical University of Gdansk, 80-211 Gdansk, Poland.

Jaroslaw Skokowski (J)

Department of Surgical Oncology, Medical University of Gdansk, 80-211 Gdansk, Poland.
Department of Medical Laboratory Diagnostics-Biobank Fahrenheit BBMRI.pl, Medical University of Gdansk, Debinki Street 7, 80-211 Gdansk, Poland.

Magdalena Niemira (M)

Clinical Research Centre, Medical University of Bialystok, 15-276 Bialystok, Poland.

Adam Kretowski (A)

Clinical Research Centre, Medical University of Bialystok, 15-276 Bialystok, Poland.

Aleksandra Markiewicz (A)

Laboratory of Translational Oncology, Intercollegiate Faculty of Biotechnology, Medical University of Gdansk, 80-211 Gdansk, Poland.

Anna J Zaczek (AJ)

Laboratory of Translational Oncology, Intercollegiate Faculty of Biotechnology, Medical University of Gdansk, 80-211 Gdansk, Poland.

Classifications MeSH